MY-O-SENSES
Financiado
Pre-clinical development of a lentiviral gene therapy to treat hearing and balan...
Pre-clinical development of a lentiviral gene therapy to treat hearing and balance loss in Usher 1B patients
The most prevalent genetic sensory defect, sensorineural hearing loss (SNHL), affects >430 million people and results in substantial financial and social consequences. Current treatment options are limited, achieving only temporar...
The most prevalent genetic sensory defect, sensorineural hearing loss (SNHL), affects >430 million people and results in substantial financial and social consequences. Current treatment options are limited, achieving only temporary or partial relief and are restricted to a sub-group of patients. Therefore, novel treatment options are of high clinical need. Genetic mutations play a role in the majority of SNHL cases, which makes SNHL an ideal setting for innovative clinical gene therapy approaches. Usher syndrome is an especially severe form of SNHL, with loss of vision and balance accompanying the profound deafness. The size of the underlying genes, mutations of which are causative for Usher syndrome, exceeds the cargo capacity of gene therapy vectors currently employed to treat inner ear disorders. In my ERC-funded consolidator project iHEAR, we have provided the first ground-breaking evidence of efficient gene transfer into inner ear cell types using beyond state-of-the-art lentiviral vectors (LV). As these LV have the capacity to deliver large genetic payloads, we acquired initial data demonstrating functional improvement in a knock-out mouse hearing loss model following LV application. The MY(O)SENSES PoC proposal aims to advance these valuable research results towards clinical application by completing pre-clinical development, securing IP rights and commercializing a formulated medicinal product to launch a first-in-human clinical LV gene therapy trial to treat Usher syndrome patients. This ground-breaking concept can be extended to treat late-onset hearing loss in patients with heterozygous mutations and can be transferred to similar diseases with a genetic or acquired cause. The MY(O)SENSES product will be the first and only treatment that addresses the debilitating vertigo in combination with treating hearing loss in Usher syndrome patients, having the potential to drastically improve patients' lives and benefit society.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2022-08-08
Fecha Fin: 2024-02-29
Fecha Fin: 2024-02-29
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-POC2:
ERC PROOF OF CONCEPT GRANTS2
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
MEDIZINISCHE HOCHSCHULE HANNOVER
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5